Ubs Group Ag Tg Therapeutics, Inc. Transaction History

Ubs Group Ag

$400 Billion
Q2 2024

A detailed history of Ubs Group Ag transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 520,232 shares of TGTX stock, worth $11.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

520,232

Previous 524,622 0.84%

Holding current value

$11.6 Million

Previous $7.98 Million 15.98%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$13.32 - $19.19 $58,474 - $84,244	-4,390 Reduced 0.84%	520,232 $9.25 Million
Q1 2024 May 13, 2024	SELL	$13.02 - $21.3 $523,586 - $856,558	-40,214 Reduced 7.12%	524,622 $7.98 Million
Q4 2023 Feb 09, 2024	BUY	$6.68 - $18.81 $1.4 Million - $3.94 Million	209,271 Added 58.86%	564,836 $9.65 Million
Q3 2023 Nov 09, 2023	BUY	$8.36 - $26.5 $1.76 Million - $5.57 Million	210,173 Added 144.56%	355,565 $2.97 Million
Q2 2023 Aug 11, 2023	SELL	$15.48 - $35.0 $1.88 Million - $4.25 Million	-121,488 Reduced 45.52%	145,392 $3.61 Million
Q1 2023 May 12, 2023	SELL	$10.23 - $19.34 $1.93 Million - $3.65 Million	-188,887 Reduced 41.44%	266,880 $4.01 Million
Q4 2022 Feb 08, 2023	BUY	$5.01 - $11.83 $2.17 Million - $5.13 Million	433,782 Added 1973.08%	455,767 $5.39 Million
Q3 2022 Nov 10, 2022	SELL	$4.57 - $8.4 $518,082 - $952,274	-113,366 Reduced 83.76%	21,985 $131,000
Q2 2022 Aug 10, 2022	SELL	$3.74 - $10.66 $69,459 - $197,977	-18,572 Reduced 12.07%	135,351 $576,000
Q1 2022 May 16, 2022	SELL	$7.81 - $20.45 $779,976 - $2.04 Million	-99,869 Reduced 39.35%	153,923 $1.46 Million
Q4 2021 Feb 14, 2022	BUY	$15.2 - $35.51 $2.62 Million - $6.13 Million	172,501 Added 212.2%	253,792 $4.82 Million
Q3 2021 Nov 15, 2021	BUY	$21.78 - $40.45 $1.63 Million - $3.03 Million	74,994 Added 1190.95%	81,291 $2.71 Million
Q2 2021 Aug 13, 2021	SELL	$32.5 - $48.96 $1.34 Million - $2.02 Million	-41,303 Reduced 86.77%	6,297 $244,000
Q1 2021 May 12, 2021	BUY	$41.61 - $54.3 $1.65 Million - $2.15 Million	39,630 Added 497.24%	47,600 $2.3 Million
Q4 2020 Feb 11, 2021	SELL	$25.27 - $54.9 $14,631 - $31,787	-579 Reduced 6.77%	7,970 $415,000
Q3 2020 Nov 12, 2020	BUY	$18.49 - $27.24 $39,235 - $57,803	2,122 Added 33.02%	8,549 $229,000
Q2 2020 Jul 31, 2020	SELL	$8.9 - $21.84 $546,958 - $1.34 Million	-61,456 Reduced 90.53%	6,427 $125,000
Q1 2020 May 01, 2020	BUY	$7.14 - $15.99 $238,354 - $533,794	33,383 Added 96.76%	67,883 $668,000
Q4 2019 Feb 14, 2020	SELL	$5.1 - $11.2 $1.23 Million - $2.7 Million	-240,699 Reduced 87.46%	34,500 $383,000
Q3 2019 Nov 14, 2019	BUY	$5.38 - $8.99 $320,680 - $535,857	59,606 Added 27.65%	275,199 $1.55 Million
Q2 2019 Aug 14, 2019	BUY	$6.27 - $8.65 $1.19 Million - $1.65 Million	190,407 Added 756.0%	215,593 $1.87 Million
Q1 2019 May 14, 2019	SELL	$4.02 - $8.04 $1.36 Million - $2.73 Million	-339,197 Reduced 93.09%	25,186 $203,000
Q4 2018 Feb 14, 2019	BUY	$3.44 - $5.76 $1.11 Million - $1.87 Million	323,887 Added 799.8%	364,383 $1.49 Million
Q3 2018 Nov 14, 2018	BUY	$5.15 - $14.0 $18,328 - $49,826	3,559 Added 9.64%	40,496 $226,000
Q2 2018 Aug 14, 2018	SELL	$12.5 - $15.0 $2.09 Million - $2.5 Million	-166,923 Reduced 81.88%	36,937 $486,000
Q1 2018 May 15, 2018	BUY	$8.7 - $16.8 $1.12 Million - $2.16 Million	128,766 Added 171.47%	203,860 $2.9 Million
Q4 2017 Feb 14, 2018	SELL	$7.35 - $12.3 $296,682 - $496,489	-40,365 Reduced 34.96%	75,094 $616,000
Q3 2017 Nov 14, 2017	BUY	$10.0 - $12.7 $969,600 - $1.23 Million	96,960 Added 524.14%	115,459 $1.37 Million
Q2 2017 Aug 14, 2017	BUY	N/A	3,893 Added 26.65%	18,499 $186,000
Q1 2017 Nov 14, 2017	BUY	N/A	14,606	14,606 $171,000

Others Institutions Holding TGTX

# of Institutions

288

Shares Held

91.8M

Call Options Held

1.9M

Put Options Held

1.45M

View Full List

About TG THERAPEUTICS, INC.

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $3.23B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

More about TGTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account